Skip to main content

Table 2 Multivariate analysis of patients’ characteristics and started on metformin (Yes/No)

From: Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines

  No (%) of patients or mean ± SD Multivariate analysis*
  Yes No OR (95% CI) p value
Patient characteristics n = 1177 n = 102   
Gender     
• Male 582 (49.5) 47 (46.1) 1.00 [Reference]  
• Female 595 (50.6) 55 (53.9) 0.85 (0.55-1.32) 0.48
Age     
• ≥65 649 (55.1) 72 (70.6) 1.0 [Reference]  
• <65 528 (44.9) 30 (29.4) 1.64 (1.09-2.48) 0.02
Co-morbidities     
Cardiovascular     
• No 1101 (93.5) 93 (91.2) 1.00 [Reference]  
• Yes 76 (6.5) 9 (8.8) 0.78 (0.37-1.66) 0.52
Renal     
• No 1167 (99.1) 95 (93.1) 1.00 [Reference]  
• Yes 10 (0.9) 7 (6.9) 0.14 (0.05-0.40) <0.0001
Drugs
Number of OHA     
• ≥2 93 (7.9) 9 (8.8) 1.00 [Reference] 0.83
• 1 1084 (92.1) 93 (91.2) 0.91 (0.37-2.19)  
Physician characteristics n=95 n=73   
MD gender     
• Male 59 (54.1) 34 (63.0) 1.00 [Reference]  
• Female 50 (45.9) 20 (37.0) 1.21 (0.66-2.23) 0.53
Practice experience (in years) (mean, SD) 21.9 (8.2) 24 (7.8) 1.00 (0.96-1.05) 0.94
MD evidence scale (mean, SD) n=90 n=52   
• <20 22 (24.4) 14 (26.9) 1.00 [Reference]  
• 20-23 53 (58.9) 31 (59.6) 0.71 (0.38-1.34) 0.29
• >23 15 (16.7) 7 (13.5) 1.16 (0.55-2.46) 0.69
Evidence guidelines
2008 CDA guidelines     
• Pre 601 (51.1) 69 (67.7) 1.00 [Reference]  
• Post 576 (48.9) 33 (32.4) 1.86 (1.20-2.90) 0.01
  1. Note: OHA Oral hypoglycemic agent, CDA Canadian Diabetes Association.
  2. *Multivariate analysis done for patients’ gender, age and co-morbidities, guidelines, MD evidence scale, gender, practice experience and drugs.
  3. Model cannot converge when an interaction term involving guideline and MD evidence scale (categorical) were included.